An Open-Label Trial to Assess the Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects
Latest Information Update: 11 Jan 2023
At a glance
- Drugs Cefepime/taniborbactam (Primary)
- Indications Pyelonephritis; Urinary tract infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors VenatoRx Pharmaceuticals
Most Recent Events
- 09 Jan 2023 Results published in the Journal of Antimicrobial Chemotherapy
- 03 May 2019 Status changed from active, no longer recruiting to completed.
- 01 May 2019 Planned End Date changed from 1 Apr 2019 to 1 May 2019.